<DOC>
	<DOCNO>NCT00686738</DOCNO>
	<brief_summary>The purpose study develop index predict response pre-operative chemotherapy osteosarcoma patient . Histologic response pre-operative chemotherapy important ultimate outcome osteosarcoma patient . Conventional method CT MRI evaluate tumor response chemotherapy efficient tumor like osteosarcoma . Instead , investigator test whether blood TGF-b1 level , PET/CT finding , MRS find well level NF-kB expression tumor tissue predict chemotherapy response osteosarcoma .</brief_summary>
	<brief_title>Development Indices Predicting Response Pre-operative Chemotherapy Osteosarcoma Patients</brief_title>
	<detailed_description>We conduct prospective trial verify validity index utilize TGF-b1 , NF-kB , PET/CT , MRS predict response neoadjuvant chemotherapy osteosarcoma patient . We assume change plasma TGF-b1 level , PET/CT magnetic resonance spectroscopy ( MRS ) finding period neoadjuvant chemotherapy well initial nuclear NF-kB expression status tumor biopsy specimen either alone combination may predict chemotherapeutic response determine histopathologic necrosis fraction tumor remove . To test , obtain TGF-b1 level , PET/CT MRS finding diagnosis follow-up ( first second/third chemotherapy cycle ) . Tumor remove . Chemotherapy regimen comprise various combination cisplatin , adriamycin , high-dose methotrexate , ifosfamide , etoposide . Indices derive TGF-b1 , PET/CT , MRS predict great 90 % necrosis fraction seek utilize statistical method .</detailed_description>
	<mesh_term>Osteosarcoma</mesh_term>
	<criteria>Karnofsky ( 15 year ) Lansky ( less 15 year ) score equal great 50 Adequate organ function : GFR &gt; 60ml/min/1.73m2 EF &gt; 50 % SF &gt; 28 % echocardiogram ANC &gt; 1.5 x 10^9/L platelet &gt; 100 x 10^9/L Obtainment inform consent parents/legal guardian and/or patient Pregnant lactating woman Cardiovascular dysfunction History previous chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>osteosarcoma</keyword>
	<keyword>transform growth factor-beta 1</keyword>
	<keyword>nuclear factor-kappa B</keyword>
	<keyword>positron emission tomography/computed tomography</keyword>
	<keyword>magnetic resonance spectroscopy</keyword>
	<keyword>predict response neoadjuvant chemotherapy</keyword>
</DOC>